[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100493893":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":38,"centralContacts":43,"locations":53,"responsibleParty":78,"collaborators":30,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":30,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":30,"overallStatus":55,"whyStopped":30,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Hôpital le Vinatier","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dopamine precursor","ACTIVE_COMPARATOR","In the first condition, volunteers will receive a dopamine (DA) precursor (L-dopa, 100mg). L-dopa will be combined with a dose of an Aromatic amino acid decarboxylase inhibitor (Benserazide) 25mg to multiplicate its bioavailability and with a dose of domperidone 10mg (peripheral antagonist of DA) to minimize the risk of side effects.",[13],"Other: Précurseur de la dopamine",{"label":15,"type":10,"description":16,"interventionNames":17},"D2 antagonist","In the second condition, volunteers will receive a D2 antagonist (Sulpiride, 800mg)",[18],"Other: antagoniste D2",{"label":20,"type":21,"description":22,"interventionNames":23},"PLACEBO","PLACEBO_COMPARATOR","In the third condition, volunteers will receive a placebo (lactose)",[24],"Other: PLACEBO",[26,31,35],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Précurseur de la dopamine","In the first condition, volunteers will receive a 100mg dose of L-dopa, 25mg dose of Aromatic amino acid decarboxylase inhibitors (Benserazide) and 10mg dose of Domperidone. In the second condition, volunteers will receive Sulpiride 800mg. In the third condition, volunteers will receive placebo Reality-monitoring performances will be evaluated with a standardized task. Working-memory will be evaluated with the n-back task. Self-monitoring performances will be observed during a speech production experiment in which speakers monitor their auditory feedback while speaking.\n\nSpeech Bayesian reasoning: This task is a home-made task investigating the influence of prior on speech processing. Subjects will be required to identify speech in ambiguous auditory stimuli. Visual Bayesian reasoning: This task investigates the influence of prior on visual processing. Subjects will be required to recognize morph between faces and house.",[9],null,{"type":6,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"antagoniste D2","In the second condition, volunteers will receive Sulpiride 800 mg",[15],{"type":6,"name":20,"description":36,"armGroupLabels":37,"otherNames":30},"In the third condition, volunteers will receive placebo",[20],[39],{"name":40,"affiliation":41,"role":42},"FILIPE GALVAO","Centre Hospitalier le Vinatier","PRINCIPAL_INVESTIGATOR",[44,49],{"name":45,"role":46,"phone":47,"phoneExt":30,"email":48},"JEROME BRUNELIN","CONTACT","0033437915565","jerome.brunelin@ch-le-vinatier.fr",{"name":50,"role":46,"phone":51,"phoneExt":30,"email":52},"VERONIQUE VIAL","0033437915522","veronique.vial@ch-le-vinatier.fr",[54],{"facility":41,"status":55,"city":56,"state":30,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"RECRUITING","Bron","69678","France","FR",{"type":61,"coordinates":62},"Point",[63,64],4.91303,45.73865,{"lat":64,"lon":63},[67,72,75],{"name":68,"role":46,"phone":69,"phoneExt":70,"email":71},"Marine Mondino","0437915565","+33","marine.mondino@ch-le-vinatier.fr",{"name":73,"role":46,"phone":74,"phoneExt":70,"email":48},"Jérôme Brunelin","0437915297",{"name":76,"role":77,"phone":30,"phoneExt":30,"email":30},"Jerome Brunelin","SUB_INVESTIGATOR",{"type":79,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100493893","reality-monitoring-and-dopamine-100493893",false,"NCT05711082","REALITY MONITORING AND DOPAMINE","The Role of Dopamine in Reality Memory","MORDOR","Inclusion Criteria:\n\n* Healthy volunteers who have given their written informed consent\n* Men and women from 18 to 45 years old\n* Normal or corrected vision\n* Being fluent in French or French for native language\n* Being affiliated with health insurance\n\nExclusion Criteria:\n\n* Healthy volunteers who have given their written informed consent\n* Men and women from 18 to 45 years old\n* Normal or corrected vision\n* Being fluent in French or French for native language\n* Being affiliated with health insurance\n* Inadmissibility of the subject's consent or refusal\n* Working-memory deficit (as controlled with MMSE score\\\u003C 23)\n* Any past or current psychiatric or somatic condition(as controlled with the Mini International Neuropsychiatric Interview, MINI)\n* Any past or current neurological condition\n* History of cranio-cerebral trauma, arterial hypotension or hypertension, cardiological or serious medical condition\n* Abnormal potassium dosage (below 3.1 mmol\u002FL or above 4.9 mmol\u002FL)\n* Anormal ECG\n* History of schizophrenia or bipolar disorder in first-degree relatives\n* Alcohol-drinking and caffeine intake at least during 24 hours before each session\n* Drug therapy excepting contraceptives\n* Cardiologic or severe medical conditio\n* Pregnancy(checked with a pregnancy autotest), lactation, or insufficient contraceptive measure (precautionary measure)\n* Consumption of recreational drugs during the last 6 months\n* Known sensitivity to any of the study medication and their excipients\n* Lactose intolerance\n* Porphyria\n* Hepatic insufficiency",true,"ALL","18 Years","45 Years",{"count":93,"type":94},39,"ESTIMATED","INTERVENTIONAL",[97],"NA","Reality-monitoring characterizes the ability to determine whether information was perceived in the environment or only imagined . Impaired reality-monitoring abilities have been associated with hallucinations in patients with schizophrenia and patients with Parkinson's disease.\n\nThe investigators hypothesize a link between dopaminergic (DA) transmission and reality-monitoring.",[100],"Neurosciences","2026-06-10",{"date":103,"type":104},"2026-06-12","ACTUAL",{"date":106,"type":104},"2024-01-15",{"date":108,"type":94},"2027-02-28",{"name":5,"class":6},1]